Abstract Search

ea0089c17 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Integration of Radioembolization with CapTem for Liver-Dominant G2 NETs: Long-Term Outcomes

Soulen Michael C. , Teitelbaum Ursina R. , Mick Rosemarie , Eads Jennifer , Mondschein Jeffrey I. , Dagli Mandeep , van Houten Diana , Damjanov Nevena , Schneider Charles , Cengel Keith , Metz David C.

Background: Capecitabine-Temozolomide (CapTem) is an effective oral chemotherapy regimen for NETs. Both drugs are radiosensitizers. A feasibility study of integrated CapTem and Y90 transarterial radioembolization (TARE) in patients with grade 2 neuroendocrine tumor (NET) liver metastases reported encouraging objective response rate (ORR) and progression-free survival (PFS). This study expands that report to a larger cohort with long-term oncologic follow-up.<p class="abste...

0 shares

ea0089c18 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Radiosensitization for TARE: Does Duration of Chemotherapy Affect PFS?List of participants and their roles in the submission

Background: Capecitabine and temozolomide (CapTem) are classic radiosensitizers used in combination with radiation therapy for many cancers. A feasibility study of integrated CapTem and Y90 transarterial radioembolization (TARE) for neuroendocrine tumors (NETs) suggests synergy with PFS of 31 months exceeding historical controls. The impact of duration of chemotherapy after TARE on PFS is not known.Methods: 36 subjects with liver-domianant grade 2 metast...

0 shares

Endocrine Abstracts

Integration of Radioembolization with CapTem for Liver-Dominant G2 NETs: Long-Term Outcomes

Radiosensitization for TARE: Does Duration of Chemotherapy Affect PFS?List of participants and their roles in the submission

BiosciAbstracts